Advanced search
Publication Cover
Core Evidence Volume 14, 2019 - Issue
Journal homepage
138
Views
17
CrossRef citations to date
0
Altmetric
Review

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy

Maria Galkin1 Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA
&
Brian A Jonas2 Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USACorrespondence[email protected]
Pages 3-17 | Published online: 26 Apr 2019

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mahesh Swaminathan & Eunice S. Wang. (2020) Novel therapies for AML: a round-up for clinicians. Expert Review of Clinical Pharmacology 13:12, pages 1389-1400.
Read now

Articles from other publishers (16)

Sahiti Chamarthy & Janaki Ramaiah Mekala. (2023) Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics. Metabolic Brain Disease 38:5, pages 1441-1469.
Crossref
Hae J. Park & Mark A. Gregory. (2023) Acute myeloid leukemia in elderly patients: New targets, new therapies. Aging and Cancer 4:2, pages 51-73.
Crossref
Rose Parisi, Emily A. Cowen, Joseph R. Stoll, Haoling Zhu, Stephen Dusza, Melissa P. Pulitzer, Eytan M. Stein & Alina Markova. (2022) Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia. Leukemia Research 123, pages 106970.
Crossref
Anselm Morell, Youssif Budagaga, Dimitrios Vagiannis, Yu Zhang, Lenka Laštovičková, Eva Novotná, Andrew Haddad, Melodie Haddad, Ramon Portillo, Jakub Hofman & Vladimír Wsól. (2022) Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters. Archives of Toxicology 96:12, pages 3265-3277.
Crossref
Aathira Sujathan Nair, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim & Bijo Mathew. (2022) FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years. Processes 10:10, pages 2054.
Crossref
Preantha Poonan, Clement Agoni, Mahmoud A. A. Ibrahim & Mahmoud E. S. Soliman. (2021) Glioma-Targeted Therapeutics: Computer-Aided Drug Design Prospective. The Protein Journal 40:5, pages 601-655.
Crossref
Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang & Shengyong Yang. (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy 6:1.
Crossref
Michael Maher, Jeannine Diesch, Marguerite-Marie Le Pannérer & Marcus Buschbeck. (2021) Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy. Cancers 13:7, pages 1746.
Crossref
Bo-wen Wang, Cheng-zheng Qiu, Chang-qian Tang, Jia-hui Zhang, Yi Zhang, Qi-guang Du, Yi Feng & Xiang-jun Qiu. (2021) UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics. BioMed Research International 2021, pages 1-8.
Crossref
Valentina Giudice, Carmine Vecchione & Carmine Selleri. (2020) Cardiotoxicity of Novel Targeted Hematological Therapies. Life 10:12, pages 344.
Crossref
Kamran Mansouri, Mohsen Rastegari-Pouyani, Maryam Ghanbri-Movahed, Mehrnoush Safarzadeh, Sara Kiani & Zahra Ghanbari-Movahed. (2020) Can a metabolism-targeted therapeutic intervention successfully subjugate SARS-COV-2? A scientific rational. Biomedicine & Pharmacotherapy 131, pages 110694.
Crossref
Justin S. Becker & Amir T. Fathi. (2020) Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation. Current Cancer Drug Targets 20:7, pages 490-500.
Crossref
Elena S. Reckzeh & Herbert Waldmann. (2019) Development of Glucose Transporter (GLUT) Inhibitors. European Journal of Organic Chemistry 2020:16, pages 2321-2329.
Crossref
F. A. Makhacheva & T. T. Valiev. (2020) Pediatric acute myeloid leukemias treatment: current scientific view. Oncohematology 15:1, pages 10-27.
Crossref
Xiaoyan Liu & Yuping Gong. (2019) Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomarker Research 7:1.
Crossref
Sonja C. Buisman & Gerald de Haan. (2019) Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies. Cells 8:8, pages 868.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.